Description:
In preliminary laboratory science studies, the investigators show that proton pump inhibitors
(PPIs) effectively inhibit human fatty acid synthase (FASN) and breast cancer cell survival.
A preliminary retrospective study shows that PPI usage in breast cancer patients during
chemotherapy significantly improved overall survival. The impact was most striking in
patients with triple negative breast cancer (TNBC). Thus, PPIs may be repositioned as safe
and effective breast cancer drugs to enhance the effect of chemotherapy.
Many of the hurdles that slow progress from target, to lead compound, to investigational
agent, to standard therapy are not barriers for the PPIs. The PPIs are FDA-approved,
chronically used, and well tolerated so the investigators can move quickly from the
laboratory to a proof of concept clinical trial. Incorporating the PPIs into standard care
will require more than the investigators propose here, but the investigators have already
plotted the additional steps needed to truly impact patient care. If successful, the data
gathered in this proposal will lend support to and guide development of a definitive
randomized trial.
Title
- Brief Title: Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
- Official Title: Inhibiting Fatty Acid Synthase to Improve Efficacy of Neoadjuvant Chemotherapy
Clinical Trial IDs
- ORG STUDY ID:
IUSCC-0555
- NCT ID:
NCT02595372
Conditions
Interventions
| Drug | Synonyms | Arms |
|---|
| Omeprazole | | High dose omeprazole treatment |
Purpose
In preliminary laboratory science studies, the investigators show that proton pump inhibitors
(PPIs) effectively inhibit human fatty acid synthase (FASN) and breast cancer cell survival.
A preliminary retrospective study shows that PPI usage in breast cancer patients during
chemotherapy significantly improved overall survival. The impact was most striking in
patients with triple negative breast cancer (TNBC). Thus, PPIs may be repositioned as safe
and effective breast cancer drugs to enhance the effect of chemotherapy.
Many of the hurdles that slow progress from target, to lead compound, to investigational
agent, to standard therapy are not barriers for the PPIs. The PPIs are FDA-approved,
chronically used, and well tolerated so the investigators can move quickly from the
laboratory to a proof of concept clinical trial. Incorporating the PPIs into standard care
will require more than the investigators propose here, but the investigators have already
plotted the additional steps needed to truly impact patient care. If successful, the data
gathered in this proposal will lend support to and guide development of a definitive
randomized trial.
Detailed Description
Primary Objective
• Estimate the rate of pathologic complete response (pCR) in patients with triple negative
breast cancer and FASN expression treated with standard neoadjuvant chemotherapy (NAC) in
combination with high dose omeprazole.
Secondary Objectives
- Quantify the number of patients with newly diagnosed TNBC with tumors that express FASN.
- Estimate the rate of pCR in patients with triple negative breast cancer (irrespective of
FASN status) treated with standard NAC in combination with high dose omeprazole.
- Describe the safety of incorporating high dose omeprazole with standard NAC.
- Estimate the biologic activity of high dose omeprazole in modulating FASN expression and
activity.
This is a single arm Phase II study. Patients should begin therapy within 7 working days of
study entry. Patients will be treated with omeprazole 80 mg orally twice a day (BID)
beginning 4-7 days prior to chemotherapy and continuing until surgery. After the brief period
of omeprazole monotherapy, patients will begin standard neoadjuvant chemotherapy with
doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) for 4 cycles followed by paclitaxel
(80 mg/m2) weekly x 12. Doxorubicin and cyclophosphamide (AC) may be administered on a
classical every 3 week or dose dense every 2 week (with growth factor support) schedule at
the treating physician's discretion. Routine incorporation of carboplatin is not recommended,
however use of carboplatin (AUC 6 on week 1, 4, 7, and 10) with paclitaxel is allowed at the
treating investigator's discretion. Chemotherapy will be adjusted based on toxicity according
to standard treatment guidelines. Patients with overt disease progression during AC should
move immediately to paclitaxel therapy. Patients with disease progression during paclitaxel
should proceed immediately to surgery.
Trial Arms
| Name | Type | Description | Interventions |
|---|
| High dose omeprazole treatment | Experimental | Patients will be treated with omeprazole 80 mg orally BID beginning 4-7 days prior to chemotherapy and continuing until surgery. | |
Eligibility Criteria
Inclusion Criteria
1. Newly diagnosed triple negative breast cancer (TNBC) clinical stage Ic, II, or III
- ER and PR < 10%
- HER2 negative based on one of the following:
- IHC 0 or 1+
- IHC 2+ and FISH negative
- IHC 2+ and FISH equivocal and no indication for HER2 targeted therapy based
on the treating investigators discretion (i.e., HER2: CEP17 ratio < 2.0 or
HER2 total copy number <6)
2. Planned neoadjuvant treatment with anthracycline and taxane containing chemotherapy
3. ≥ 18 years old at the time of informed consent
4. ECOG Performance Status 0-1
5. Ability to provide written informed consent and HIPAA authorization
6. Women of childbearing potential definition must have a negative pregnancy test within
14 days of registration. All women (regardless of sexual orientation, having undergone
a tubal ligation, or remaining celibate by choice) are considered to have childbearing
potential unless they meet one of the following criteria:
- Prior hysterectomy or bilateral oophorectomy;
- Has not had menses at any time in the preceding 24 consecutive months
7. Adequate organ function for anthracycline and taxane based therapy
- LVEF > LLN based on cardiac ECHO or MUGA
- Hgb > 8.5
- ANC > 1,000
- Platelets > 100,000
- Creatinine < 1.5
- T. bili < 1.3
- AST < 2.5 x ULN
Exclusion Criteria
1. Use of prescription PPIs within 12 months prior to study entry [Dexlansoprazole
(Dexilant), Pantoprazole (Protonix), Rabeprazole (Aciphex), Esomeprazole (Nexium),
Lansoprazole (Prevacid), Omeprazole (Prilosec, Zegerid)]
2. Use of OTC PPIs within 6 months prior to study entry [Esomeprazole (Nexium),
Lansoprazole (Prevacid), Omeprazole (Prilosec, Zegerid)]
3. Use of Orlistat or any other known FASN inhibitor within 6 months prior to study entry
4. Nursing mothers are excluded
5. Known hypersensitivity to any component of the formulation or substituted
benzimidazoles
6. Prior osteoporotic fracture
| Maximum Eligible Age: | N/A |
| Minimum Eligible Age: | 18 Years |
| Eligible Gender: | All |
| Healthy Volunteers: | No |
Primary Outcome Measures
| Measure: | Percentage of Patients With Pathological Complete Response (pCR) in Patients Who Have Fatty Acid Synthase (FASN) Expression |
| Time Frame: | Up to 6 months |
| Safety Issue: | |
| Description: | pCR is defined as no invasive disease in the breast of axilla at the time of definitive surgery. A patient is considered to have FASN expression if the positivity was >= 15% at the baseline or after 4-7 days of Omeprazole monotherapy. FASN expression is evaluated using immunohistochemistry in core biopsy samples. The percent of patients with FASN expression that have pCR will be calculated with an exact 95% confidence interval. |
Secondary Outcome Measures
| Measure: | Percentage of Patients With Pathological Complete Response (pCR) in All Patients |
| Time Frame: | Up to 6 months |
| Safety Issue: | |
| Description: | pCR is defined as no invasive disease in the breast or axilla at the time of definitive surgery. The percentage of patients who achieve pCR along with exact 95% confidence intervals were calculated. |
| Measure: | Percent of Patients With FASN Expression |
| Time Frame: | up to 1 week |
| Safety Issue: | |
| Description: | FASN expression was evaluated using immunohistochemistry in core biopsy samples. FASN expression was determined if the positivity was >= 15%. The percent of patients who had FASN expression and the exact 95% confidence intervals were calculated. |
| Measure: | FASN Positivity Expression at Baseline and After 4-7 Days of Omeprazole Treatment |
| Time Frame: | baseline and after 4-7 days |
| Safety Issue: | |
| Description: | The mean and standard deviation of FASN positivity expression determined at baseline and after 4-7 days of Omeprazole treatment. FASN expression is evaluated using immunohistochemistry in core biopsy samples. |
| Measure: | FASN Activity at Baseline and After 4-7 Days of Omeprazole Treatment |
| Time Frame: | baseline and after 4-7 days |
| Safety Issue: | |
| Description: | The mean and standard deviation of FASN activity determined at baseline and after 4-7 days of Omeprazole treatment. FASN activity was evaluated using immunohistochemistry in core biopsy samples. |
| Measure: | Number of Patients With Treatment Related Adverse Events Grade 3 or Above |
| Time Frame: | up to 8 months |
| Safety Issue: | |
| Description: | Number of unique patients who had an Omeprazole treatment related (possible, probable or definite) adverse event with grade >= 3. |
Details
| Phase: | Phase 2 |
| Primary Purpose: | Interventional |
| Overall Status: | Completed |
| Lead Sponsor: | Kathy Miller |
Last Updated
April 8, 2021
